drugset

drugset / Trial / NCT06703268

A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients

NCT06703268 ↗

Phase 2 Completed 64 enrolled Haisco Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the effectiveness of HSK7653 tablets following the substitution of daily DPP-4 inhibitor (DPP-4i) over a 24-week treatment period.

Timeline

Start: 2024-01-15
Primary completion: 2024-10-05
Completion: 2024-11-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK7653	Unknown	10 mg	—

Indications